Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2's main protease.

ABSTRACT:

Background

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in millions of infections worldwide. While the search for an effective antiviral is still ongoing, experimental therapies based on repurposing of available antivirals is being attempted, of which HIV protease inhibitors (PIs) have gained considerable interest. Inhibition profiling of the PIs directly against the viral protease has never been attempted in vitro, and while few studies reported an efficacy of lopinavir and ritonavir in SARS-CoV-2 context, the mechanism of action of the drugs remains to be validated.

Methods

We carried out an in-depth analysis of the efficacy of HIV PIs against the main protease of SARS-CoV-2 (M^pro) in cell culture and in vitro

SUBMITTER: Mahdi M 

PROVIDER: S-EPMC7689640 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature